Tizanidine — Central alpha-2 adrenergic agonist (antispastic). Study the mechanism, listed uses and warnings from the US label on one sourced card.
Generic name
Tizanidine
Class
Central alpha-2 adrenergic agonist (antispastic)
Mechanism
Central alpha-2 adrenergic agonist presumed to reduce spasticity through increased presynaptic inhibition of motor neurons, with the greatest effects on polysynaptic pathways.
Fluvoxamine / ciprofloxacin (contraindicated); Other CYP1A2 inhibitors; Oral contraceptives
Brand questions use only name pairings verified against the linked product source. Unverified pairings are withheld from these questions; the other study content remains available.
Label date: 20260825 · For learning, not clinical decisions. US label and brand information; always consult the current source.
Source snapshot checked: 2026-10-21. The source document and selected fields were compared. The complete card has not had an independent clinical review.
Mechanism: Relieves skeletal muscle spasm of local origin without interfering with muscle function. Animal studies support a mainly central action rather than a direct action at skeletal muscle or the neuromuscular junction.
On both cards: Common side effects — Dry mouth; Somnolence; Dizziness
Only on the Cyclobenzaprine card: Used for — Short-term relief of muscle spasm from acute, painful musculoskeletal conditions, as an adjunct to rest and physical therapy · Common side effects — Fatigue; Constipation · Warnings — Serotonin syndrome; TCA-like cardiovascular / CNS effects; Not recommended in elderly or hepatic impairment; The selected extended-release capsule is intended only for short periods, up to 2–3 weeks; effectiveness for central spasticity has not been established · Interactions — MAO inhibitors; Alcohol, barbiturates, CNS depressants; Tramadol
An item counts as shared only when both cards use the same wording. If a card does not list an item, that is not a statement that the effect never occurs.
Capsera